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8. Publications and abstracts
1.  Introduction
      p21/WAF1/Cip1 (referred to as p21 hereafter) was originally 
identified as a downstream effector of p53-mediated block of cell 
cycle progression whose physiological function is to act as an 
universal inhibitor of cyclin-dependent kinase (cdk) activities. 
Besides its function in controlling cell proliferation, p21 has been 
reported to function as a transcriptional regulator, and this second 
role appears to be independent of its cell cycle regulatory activities. 
p21 inhibits transcriptional activation exerted by several 
transactivators, including E2F (Delavaine and LaThangue, 1999), 
STAT3 (Coqueret and Gascan, 2000), and myc (Kitaura et al., 
2000). Its role in transcriptional repression has also been described 
for promoters of polo-like kinase 1 and topoisomerase II(Zhu et 
al., 2002), survivin (Lohr et al., 2003), and Wnt4 (Devgan et al., 
2005), and others.  In other circumstances, p21 functions as a 
transcriptional coactivator stimulating the transcription by 
estrogene receptor (Fritah et al., 2005) or NFkappaB (Poole et al., 
2004). Transcription of the p21 is induced during differentiation of 
several cell types in the cell culture models, including 
oligodendrocytes (Zezula et al., 2001), chondrocytes (Negishi et al.,  
2001), or feochromocytoma cells (Erhardt and Pittman, 1998).
      In this study, the role of p21 has been investigated in the mouse 
embryonal carcinoma F9 cells. Simultaneous treatment with RA 
and dibutyryl-cAMP or other agents that stimulate the cAMP 
pathway converts F9 cells into cells with a phenotype reminiscent 
of parietal endoderm (PE) (Strickland et al., 1980). We examined 
the changes in cell cycle-related proteins during the differentiation 
of F9 cells into PE. We found that the p21 protein increases during 
differentiation, reaching high levels at the end of a 6-day 
differentiation period. The p21 protein transcriptionally upregulates 
the PE-specific marker TM, and partially localizes to the cytoplasm 
in a subset of differentiated cells, indicating that it may have an 
antiapoptotic role in differentiated cells. 
      In the melanocyte, the transcription of p21 seems to be 
governed by MITF (Carreira et al., 2005), a master regulator of 
melanocyte differentiation and proliferation (Goding, 2000; Vance 
and Goding, 2004; Levy et al., 2006). The expression of the 
melanocyte-specific isoform of MITF is uniformly conserved and 
upregulated in human malignant melanocytes and an increasing 
number of data support its role in melanoma cell survival and 
proliferation. Numerous MITF targets have been identified so far, 
including melanocyte markers, cdk2, c-met, HIF1, and cdk 
inhibitors p21 and p16. The overexpression of MITF was 
commonly observed in the majority of melanoma cell lines and 
tissue samples. The p21 protein was found to be abundantly 
expressed in melanoma specimens and cell lines (Trotter et al., 
1997). Whether the p21 protein has any cell cycle regulatory role in 
malignant melanocytes and why the relatively high protein levels 
are tolerated by melanoma cells remains unresolved. In an attempt 
to determine a potential cell cycle-independent role of p21 in 
transformed melanocytes, we explored its functional participation 
in expression of pigment cell-specific genes. 
     The E1A 12S oncoprotein of the adenovirus is a strong 
transcriptional repressor. When expressed in the cell, E1A binds 
strongly to and inactivates the paralogous coactivators and histone 
acetyltransferases (HATs) p300 and CBP (Frisch and Mymryk, 
2002). Apart from neutralizing p300/CBP, transcription inhibition 
can also be accomplished via targeting additional HATs and 
coactivators such as PCAF, hGCN5, p400 and TRRAP (Deleu et 
al., 2001; Frisch and Mymryk, 2002; Lang and Hearing, 2003; 
Shuen et al., 2002). The E1A’s ability to repress transcription 
generally requires the N-terminus and the conserved region 1 
(CR1). Mouse melanocytes, as well as several other cell types, can 
be immortalized by the adenoviral E1A 12S oncoprotein. In E1A-
expressing melanocytes, MITF and its target genes are fully 
extinguished (Halaban et al., 1996; Yavuzer et al., 1995). These 
dedifferentiated melanocytes do not require MITF for survival, 
presumably due to the immortalizing activity of E1A. The E1A 
protein is also known to exert an antitumour activity, which is 
associated with its transcription repression function and the ability 
to induce apoptosis, and is a potential antimelanoma agent 
(reviewed by Frisch and Mymryk, 2002). In this study, the effect of 
E1A on the MITF promoter and MITF target promoters was 
investigated. 
2. Aims of the study
   The role of the p21(WAF1) protein in F9 cells which 
differentiate into parietal endoderm: 
- expression of the protein, role in cell cycle regulation 
- transcriptional effects of p21 independent  of  cell 
proliferation, regulation of  PE marker 
thrombomodulin
   Investigation of a role of p21 protein in transcription of 
melanocyte-specific genes: 
- functional role in the regulation of MITF promoter
- mechanisms of transcriptional regulation by the p21 
protein
   The effect of adenoviral protein E1A on the expression of 
MITF and its downstream targets – an effective way to down-
regulate MITF function and inhibit proliferation of  melanoma 
cells:
- inhibition of the MITF promoter
- repression of MITF target gene tyrosinase
- repression of MITF target gene by E1A subregions
   Construction and functional analysis of dominant-negative 
MITF-mutant which inhibits the activity of endogenous MITF:
-    analysis of the two transcription activation domains of 
      MITF on the endogenous target promoter 
-    construction of a strong dominant-negative MITF 
     mutant
3. Methods
      The following methods were used in the study and are 
described in detail in the thesis and the cited published papers: 
Construction of expression plasmids and promoter-reporters, 
analysis of gene expression by Northern blotting, RT-PCR, and 
Western blotting, gene transfer into cultured cells, 
immunofluorescence, flow cytometry, protein-protein interactions 
(pull-down and immunoprecipitation), DNA-protein interaction by 
gel-shift, siRNA- and shRNA-mediated knock-down of gene 
expression, gene transfer (transfections), gene reporter assays, 
protein kinase assays.
4. Summary of results
4.1  The role of p21(WAF1/Cip1) protein in differentiation of F9 
embryonal carcinoma cells into parietal endoderm. 
     It is shown that the levels of cyclin-dependent kinase inhibitor 
p21/WAF1/Cip1 (p21) protein and mRNA are dramatically 
elevated at the end of differentiation into parietal endoderm (PE), 
concomitantly with the appearance of p21 in the 
immunoprecipitated CDK2–cyclin E complex. The induction of 
differentiation markers could not be achieved by expression of 
ectopic p21 alone and still required treatment with differentiation 
agents. Clones of F9 cells transfected with sense or antisense p21 
cDNA constructs revealed, upon differentiation, upregulated levels 
of mRNA for thrombomodulin, a parietal endoderm-specific 
marker, or increased fraction of cells in sub-G1 phase of the cell 
cycle, respectively. Consistent with this observation, whereas p21 
was strictly nuclear in undifferentiated cells, a large proportion of 
differentiated cells had p21 localized also in the cytoplasm, a site 
associated with the antiapoptotic function of p21. Furthermore, p21 
activated the thrombomodulin promoter in transient reporter assays 
and the p21 mutant defective in binding to cyclin E was equally 
efficient in activation. The promoter activity in differentiated cells 
was reduced by cotransfection of p21-specific siRNA or antisense 
cDNA. Coexpression of p21 increased the activity of the GAL-
p300(1–1303) fusion protein on the GAL sites-containing TM 
promoter. This implies that p21 might act through a derepression of 
the p300 N-terminal-residing repression domain, thereby enhancing 
the p300 coactivator function. As differentiation of F9 cells into 
parietal endoderm-like cells requires the cAMP signaling, the 
results together suggest that the cyclin-dependent kinase inhibitor 
p21 may promote specifically this pathway in F9 cells.
4.2   p21(WAF1/Cip1) is expressed in melanoma cells and activates 
the promoter of MITF, a master transcription regulator of 
melanocytes 
      This part of the study investigated the expression and 
transcriptional activity of p21/WAF1/Cip1 (p21) in human 
melanoma cells in culture. We found no correlation between
proliferation and p21 protein level in unsynchronized cell 
populations of melanoma cells. p21 was expressed also in 
proliferating epidermal melanocytes and clones of melanoma cells 
with p21 knocked-down by siRNA had even decreased growth 
rates. We further found that promoters of several genes related to 
differentiation were stimulated by p21 overexpression, including 
the MITF promoter. The N-terminal portion and intact cyclin-
binding site was essential for these transcription activities, 
suggesting that mechanisms other than cell cycle inhibition, PCNA 
binding, and derepression of p300/CBP repression domain CRD1 
underlie the transcriptional effects. Since activation of the p21 gene 
expression by MITF was described previously, the reciprocal 
stimulation suggested here might represent a positive-feedback 
loop reinforcing the presumed prosurvival activity of MITF in 
melanoma cells. The results further suggest that p21 may have a 
role in MITF expression rather than in cell cycle regulation in 
melanoma cells.
4.3  Adenoviral E1A protein inhibits both MITF expression and 
MITF-dependent  transcription 
      We tested a direct repression of the melanocyte-specific MITF 
promoter by E1A and its mutants. We found that the extreme N-
terminus and conserved region 1 are required for repression. In 
contrast, the motif in conserved region 2, as well as amino acids 
26-35 at the N-terminus, are not necessary. As these two later 
motifs mediate E1A binding to the retinoblastoma protein or to the 
transcriptional co-activator TRRAP, respectively, and are important 
for transformation by E1A in cooperation with other oncogenes, the 
results suggest that the transformation-defective E1A can still 
efficiently repress the MITF promoter. The CREB binding motif-
mutated promoter had lower activity, but was also repressed by the 
same   E1A mutants in human melanoma cells. Since recent data 
suggest that MITF may be a survival factor for melanoma cells, the 
E1A mutants described here might constitute a good targeting 
agent for antimelanoma therapy.
      We further used the E1A oncoprotein and its mutants as 
repressors of both the transiently transfected and endogenous 
tyrosinase promoter, which is a well-established MITF target. It is 
shown that the requirement of the E1A N-terminus for repression 
of the MITF-activated tyrosinase promoter and the sensitivity to 
derepression by the histone deacetylase inhibitor trichostatin A are 
distinct when the activity of the transiently transfected or the 
endogenous promoter is analysed in U2-OS cells. Thus, for 
transiently transfected versus chromatin-embedded promoter, the 
activity of obligatory MITF seems to be executed through different 
mechanisms of transcriptional coactivation.
4.4  Inhibition of MITF function independent of targeting 
p300/CBP coactivators - CR1 E1A domain as an autonomous 
repressor of MITF-directed transcription
      Although numerous MITF-dependent downstream genes have 
been identified, the mechanisms by which the MITF activity is 
coregulated remain elusive. We used a non-melanocytic cell line 
U2-OS as a model in which MITF evokes transcription of a MITF 
target tyrosinase and show that the adenoviral E1A protein 
represses the MITF-driven transcription in these cells. The E1A 
CR1 domain (which alone is insufficient to bind p300) was 
sufficient for repression, while the N-terminus, through which E1A 
binds the p300/CBP proteins and other coactivators, was unable to 
repress. Correspondingly, CR1 inhibited colony formation of 
MITF-positive, but not MITF-negative, melanoma cells. The 
repression by CR1 was largely independent of the PCAF-binding 
motif, previously recognized to be necessary for suppression of 
muscle-specific enhancer. Interestingly, CR1 conferred 
transcriptional competence to the MITF-CR1 chimera in which the 
MITF portion was rendered transcription-deficient. Moreover, 
MITF mutants defective in binding to p300/CBP in vivo still 
activated transcription, further supporting a p300/CBP-independent 
coactivation of MITF targets. MITF is amplified in a subset of 
melanomas and is thought to be required for sustained proliferation 
of malignant melanocytes. Our results suggest that understanding 
how CR1 represses Mitf activity may reveal a route to melanoma 
therapy.
4.5 Dominant-negative MITF mutant - identification of a second 
transcription activation domain in MITF 
      A dominant negative mutant of the melanocyte-specific isoform 
of MITF is described carrying deletions of both N- and C-terminal 
transactivation domains. Cotransfection of this mutant resulted in a 
complete inhibition of the wild type MITF function as tested on 
both the reporter-linked tyrosinase promoter and an endogenous, 
ectopic MITF-triggered tyrosinase gene in U2-OS cells. The 
dominant negative construct also strongly repressed the activity of 
a hyperactive MITF-Vp16 chimera. Importantly, deletion of both 
activation domains was necessary to eliminate the residual 
transcription activity observed when only the N-terminal domain 
was removed and to achieve the repressive effect in human 
melanoma cells. If the activity of MITF plays a role in the long-
term survival of malignant melanocytes, overexpression of a strong 
dominant negative MITF mutant might be another useful strategy 
to suppress its transactivation function.
5. Conclusions
Transcriptional activities of p21:
The p21 protein has a role in the differentiation of F9 cells into 
PE. This role is independent of its function to inhibit cell cycle 
progression and proliferation. p21 activated the thrombomodulin 
promoter-reporter (a specific PE marker), stimulated expression of 
endogenous thrombomodulin, and partly relocalized to the 
cytoplasm in the differentiated cells, likely having an antiapototic 
role. 
We showed the positive action of p21 on the MITF promoter in 
melanoma cells, suggesting the existence of a positive-feedback 
loop constituted by reciprocal transcriptional activation between 
MITF and p21 in melanoma cells. The mechanism of coactivation 
of transcription is, for the MITF promoter, independent of its 
activity to derepress the p300/CBP CRD1 domain. 

Mechanism of MITF function:   
The activity of MITF promoter and MITF target promoters is 
repressed by the adenoviral E1A protein. MITF transcriptional 
activity on the transfected versus an endogenous, chromatin-
organized target promoter is coactivated by different mechanisms.   
We showed that unlike the N-terminus of E1A, the CR1 
domain alone is surprisingly sufficient to autonomously repress 
transcription of the MITF-evoked target gene and inhibit colony 
formation of MITF-positive melanoma cells. The CR1 might target 
as yet unidentified cofactor for MITF. 
We describe construction of a dominant negative mutant of the 
melanocyte-specific isoform of MITF carrying deletions of both N-
and C-terminal transactivation domains. This mutant has a strong 





      F9 cells (embryonal carcinoma) can be induced to differentiate 
with retinoic acid and dibutyryl-cAMP into cells with a phenotype 
resembling parietal endoderm. We show that the levels of cyclin-
dependent kinase inhibitor p21/WAF1/Cip1 (p21) protein and 
mRNA are elevated at the end of this differentiation. Clones of F9 
cells stably expressing ectopic p21 revealed, upon differentiation, 
upregulated levels of mRNA for thrombomodulin, a parietal 
endoderm-specific marker. Furthermore, p21 activated the 
thrombomodulin promoter in transient reporter assays. The 
promoter activity in differentiated cells was reduced by 
cotransfection of p21-specific siRNA or antisense cDNA. Further 
experiments suggested that p21 might act through a derepression of 
the p300 N-terminal-residing repression domain, thereby enhancing 
the p300 coactivator function. Whereas p21 was strictly nuclear in 
undifferentiated cells, a large proportion of differentiated cells had 
p21 localized also in the cytoplasm. As differentiation of F9 cells 
into parietal endoderm-like cells requires the cAMP signaling, the 
results together suggest that the cyclin-dependent kinase inhibitor 
p21 may promote specifically this pathway in F9 cells and may 
have an antiapoptotic role in these cells.
      Further study investigated the expression and transcriptional 
activity of p21 in human melanoma cells in culture. p21 was 
abundantly expressed in melanoma cells and was expressed also in 
proliferating epidermal melanocytes. We further found that 
promoters of several genes related to differentiation were 
stimulated by p21 overexpression, including the MITF promoter. 
The N-terminal portion and intact cyclin-binding site was essential 
for these transcriptional activities, suggesting that mechanisms 
other than cell cycle inhibition, PCNA binding, and derepression of 
p300/CBP repression domain CRD1 underlie the transcriptional 
effects. Since activation of the p21 gene expression by MITF was 
described previously, the reciprocal stimulation suggested here 
might represent a positive-feedback loop reinforcing the presumed 
prosurvival activity of MITF in melanoma cells. 
      Since recent data implicate MITF as a survival factor for 
melanoma cells, we further tested whether the melanocyte-specific 
MITF promoter activity can be inhibited directly by an adenoviral 
protein E1A and its mutants. We found strong repression by the 
wild type E1A protein. The two motifs which mediate E1A binding 
to the retinoblastoma protein or to the transcriptional co-activator 
TRRAP, and are important for transformation by E1A in 
cooperation with other oncogenes, were dispensable for repression. 
Thus, this transformation-defective E1A mutant might constitute a 
good targeting agent for antimelanoma therapy. We further used 
the E1A oncoprotein and its mutants as repressors of both the 
transiently transfected and endogenous tyrosinase promoter. We 
have shown that the requirement of the E1A N-terminus for 
repression of the MITF-activated tyrosinase promoter and the 
sensitivity to derepression by the histone deacetylase inhibitor 
trichostatin are distinct when the activity of the transiently 
transfected or the endogenous promoter is analysed. Thus, for these 
two promoter versions, the activity of obligatory MITF seems to be 
executed through different mechanisms of transcriptional 
coactivation.
      We have shown that the adenoviral E1A protein represses the 
MITF-driven transcription. The E1A CR1 domain (which alone is 
insufficient to bind p300) was sufficient for repression, while the 
N-terminus, through which E1A binds the p300/CBP proteins and 
other coactivators, was unable to repress. Correspondingly, CR1 
inhibited colony formation of MITF-positive, but not MITF-
negative, melanoma cells. The repression by CR1 was largely 
independent of the PCAF-binding motif. Interestingly, CR1 
conferred transcriptional competence to the MITF-CR1 chimera in 
which the MITF portion was rendered transcription-deficient. 
Moreover, MITF mutants defective in binding to p300/CBP in vivo 
still activated transcription, further supporting a p300/CBP-
independent coactivation of MITF targets. Our results suggest that 
CR1 may target an unknown cofactor which is required for Mitf 
activity.
      Also, a dominant negative mutant of the melanocyte-specific 
isoform of MITF is described carrying deletions of both N- and C-
terminal transactivation domains. Cotransfection of this mutant 
resulted in a complete inhibition of the wild type MITF function as
tested on both the reporter-linked tyrosinase promoter and an 
endogenous promoter. The dominant negative construct also 
strongly repressed the activity of a hyperactive MITF-Vp16 
chimera. Importantly, deletion of both activation domains was 
necessary to eliminate the residual transcription activity observed 
when only the N-terminal domain was removed and to achieve the 
repressive effect in human melanoma cells. If the activity of MITF 
plays a role in the long-term survival of malignant melanocytes, 
overexpression of a strong dominant negative MITF mutant might 
be a useful strategy to suppress its transactivation function.
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